Adam Yusim (@AdamYusimBio) header
Adam Yusim (@AdamYusimBio) profile picture

Hindsight is infallible. Real edge is knowing luck from skill and pressing high-conviction bets. Clinical-stage biotech and equity research. Not advice.

Canada
Joined May 2023
Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)Photo by Adam Yusim (@AdamYusimBio)
Scorpion Capital just dropped a 297-page short report on $ABVX, comparing obefazimod to DDT, dioxins, and livestock dewormer.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientific abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
3
11
3
113
18,550
Fair take, Andre, and I respect separating the noise from the real clinical questions. That said, the two concerns raised around the North America subgroup look much less alarming once you check the endpoint math and look at the broader Western population in ABTECT. $ABVX 1/
$ABVX last tweet on the subject Scorpion has a lot of questionable analysis of the MOA and TRAE. Most of that have been answered by the data so far. But the subgroup analysis of the US pts is concerning (page 292) There so many red flags in this table that would make the approval unpredictable. For example lack of correlation bn Endoscopic improvement and clinical remission in North America pbo No need to agree 100% with Scorpion, they just have an agenda, but they have some valid points
3
17
2,569
The FDA will certainly run regional sensitivity checks on the NDA. With Western Europe clearly hitting centrally read endoscopy and histology on 50 mg and North America directionally aligned on remission and safety, this looks like standard small-N subgroup variance…
1
4
267
rather than an approval blocker.
2
252
Adam Yusim retweeted
Listen. I'm Adam enough to admit when I've been out-Adam'd. If you're looking for scientific rebukes of some of the finer technical points in the Scorpion $ABVX report, read through this thread. Fortunately for all of us, essentially all of the points are so easily disproven that each refutation only requires a single line of text. This dude bodies Scorpion here. Absolute Adam.
Scorpion Capital just dropped a 297-page short report on $ABVX, comparing obefazimod to DDT, dioxins, and livestock dewormer.
2
5
2
222
15,389
$ABVX - You nailed it, & they actually put that playbook in writing on page 2. Their disclosure states that upon publication they intend to begin covering a substantial portion of their short position, & may have already covered most or all of it by the time anyone reads it.
$ABVX terrific work but IMO Scorp has likely already largely exited this position. They may retain a small position to say "we are short". The real goal is a "wham bam, thank you biotwitter," move and then onto the next target. Scientific accuracy is not particularly important in all of this.
1
1
8
1,497
Dropping a 297-page PDF on monthly OPEX day to trigger a 22% intraday flush to $62.70 before the stock bounced right back to $73.20 tells the whole story. IMO, and many others’ opinions, they were trading the initial headline panic, not betting on an FDA rejection. $ABVX
5
453
Appreciate that, Adam. I mostly just dig into the names I own, and reading your breakdowns every day is a big part of how I learned to spot the noise in biotech. Means a lot getting the nod from the real authority on this app $ABVX 👊🏻
Listen. I'm Adam enough to admit when I've been out-Adam'd. If you're looking for scientific rebukes of some of the finer technical points in the Scorpion $ABVX report, read through this thread. Fortunately for all of us, essentially all of the points are so easily disproven that each refutation only requires a single line of text. This dude bodies Scorpion here. Absolute Adam.
3
38
1,971